NCT03204799

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could influence on developing diabetes and obesity. Recent studies investigates microbiota by metagenomic sequencing, however, the composite of microbiota and its metabolic role has not been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic disorders and suggest treatment options for metabolic diseases. In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.

Detailed description

1. Cross-section study: normal/prediabetes/drug naïve type2 diabetes: compare microbiota using metagenomic sequencing among three groups. 2. Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2) inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after drug treatment.

Conditions

• Type 2 Diabetes Mellitus
• Dyslipidemias

Interventions

Type	Name	Description
OTHER	Metformin	newly diagnosed type 2 diabetes patients who start to metformin monotherapy
DRUG	SGLT2 inhibitor	newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
DRUG	ezetimibe	newly diagnosed dyslipidemia patients who start to ezetimibe therapy

Timeline

• Start date: 2016-12-17
• Primary completion: 2019-09-01
• Completion: 2019-12-16
• First posted: 2017-07-02
• Last updated: 2019-01-10

Locations

1 site across 1 country: South Korea